Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai to Discontinue Tazverik in Japan over Secondary Cancer Risk
Eisai said on March 19 that it will terminate sales of its cancer drug Tazverik (tazemetostat) in Japan following safety concerns over secondary hematologic malignancies, which had already prompted its French partner Ipsen to withdraw the product in overseas markets.…
To read the full story
Related Article
- Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026
- Eisai Rolls Out Tazverik for EZH2-Positive Follicular Lymphoma
August 17, 2021
BUSINESS
- Rising Costs Squeeze Generic Firms, Spur Calls for Unprofitable Drug Re-Pricing in 2027
April 8, 2026
- BMS Files to Fully Localize Breyanzi Production in Japan
April 8, 2026
- Japan Ethical Drug Sales Surge 7.7% in February: Crecon
April 8, 2026
- Sanofi to Launch Voluntary Buyout Program, Targets General Medicines Unit
April 7, 2026
- Toho’s VC Arm Makes First Investment in US AI Antibody Startup
April 7, 2026
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…